Biogen's last-ditch pitch for an injunction to protect Tecfidera is denied, paving way for Mylan generic
After a long and drawn-out court fight, it seems all but inevitable that a generic version of Biogen’s blockbuster Tecfidera will hit the market sometime later this year.
The Cambridge, MA-based company’s last-ditch efforts to stop a Mylan generic fell flat Thursday, as a federal appellate court denied Biogen an injunction in a ruling last month invalidating Biogen’s ‘514 patent for the multiple sclerosis drug. Had the patent not been wiped out, Biogen would have delayed generic competition until 2028.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
